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Abstract 
The first aim of the current study was to investigate the pharmacokinetics of oral 
meloxicam tablets and the gastrointestinal and renal effects after a 14-day treatment period.  
Meloxicam was orally administered to six adult horses once daily at a dosage of 0.6 mg/kg for 14 
consecutive days.  Blood was collected prior to each administration and at 20 and 40 min, and 1, 
2, 4, 8, 12, and 24 hours after administration on days 1, 7, and 14 for the determination of 
meloxicam plasma concentrations by mass spectrometry.  In addition, trough samples were taken 
on days 3 and 10.  Complete blood count, serum biochemical analysis, urinalysis, and 
gastroscopy were performed at baseline and conclusion of the investigation. 
Complete blood count, serum chemistry, and urinalysis results were unchanged through 
the study period.  Gastroscopy scores were not significantly increased.  The Cmax was 1.82 ± 0.80 
µg/mL at Tmax 3.48 ± 3.30 hr on day 1, 2.07 ± 0.94 µg/mL at Tmax 1.24 ± 1.24 hr on day 7, and  
1.81 ± 0.76 µg/mL at 1.93 ± 1.30 h on day 14 (p = 0.30).  The mean half-life was 4.99 ± 1.11 h. 
The second aim of the study was to compare the analgesic effects and gastrointestinal and 
renal adverse effects of oral meloxicam tablets (0.6 mg/kg) to oral phenylbutazone tablets (4.4 
mg/kg) orally once daily for 4 days in induced and naturally occurring lameness in adult horses.  
The study was performed on 4 healthy but lame adult horses.  Complete blood count, serum 
biochemistry, urinalysis, and gastroscopy were performed prior to entrance to the study.  
Lameness was exacerbated in two horses using lipopolysaccharide (LPS; E. coli O55:B5) 
injected into the right metacarpophalangeal joint.  The remaining two horses had Grade 3 or 
Grade 4 lameness due to naturally occurring laminitis.  Meloxicam or phenylbutazone was 
administered to two horses each in a blinded, randomized manner once daily for four days.  
Lameness was evaluated using a pressure mat system and contact pressure, force, and stride 
length were evaluated at baseline and twice daily. 
Complete blood count, serum chemistry, and urinalysis were unremarkable for all four 
horses except one horse with an increased GGT.  This horse experienced hepatic rupture 
secondary to amyloidosis the final day of the study.  Gastric ulcer scores did not change during 
the study period.  Phenylbutazone administration resulted in a greater response (force and contact 
area) in the right front and left hind limbs compared to meloxicam administration.  There were 
not enough data points to evaluate the other two limbs. 
  
A third aim of the study was two-fold and first evaluated the effects of ex vivo stimulation 
of peripheral blood mononuclear cells (PBMCs) with LPS on cyclooxygenase (COX) 
messenger RNA (mRNA) expression.  The second portion documented the effects of LPS-
induced joint inflammation and treatment with non-steroidal anti-inflammatory drugs on the 
mRNA and protein expression of COX-2 in PBMCs.  The results indicate that LPS upregulates 
COX-2 gene expression in PBMCs.  Additionally, injection of LPS into the metacarpophalangeal 
joint increases both COX-2 mRNA and protein expression in PBMCs at 24 hours after injection.  
The relative expression of COX-2 after treatment with meloxicam or phenylbutazone indicates a 
stronger inhibition with phenylbutazone; however, further study with additional horses is needed. 
Pharmacokinetic analysis of the oral tablet formulation of meloxicam indicates the 
pharmacokinetics are similar to the oral suspension formulation.  Meloxicam appears to be 
inferior to phenylbutazone in its analgesic properties for induced lameness and naturally 
occurring laminitis, however the small sample size used in the study makes interpretation 
difficult. 
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Chapter 1 - Introduction 
As one of the most common and most troublesome of all equine ailments, lameness 
remains the primary reason why horses are unable to fulfill their potential and their owners’ 
expectations.  More preparation time is lost, more competitions are missed, and more careers are 
ended prematurely because of lameness than any other condition.  Osteoarthritis, tendon and 
ligament injuries, and sepsis of a joint are frequently diagnosed in the equine athlete and pasture 
pet.  Medications and therapies such as non-steroidal anti-inflammatory drugs (NSAIDs), 
platelet rich plasma, mesenchymal stem cell therapy, glucosamine/chondroitin neutraceuticals, 
physical therapy, and extracorporeal shock wave treatment have all been evaluated as treatment 
options for lameness; however, NSAIDs remain the mainstay of therapy. 
Non-steroidal anti-inflammatory drugs are the most commonly used medications in the 
equine medical world.  They are used to treat pain and inflammation due to colic, lameness, 
surgical interventions, and other medical procedures.  Additionally, their anti-thrombotic, anti-
pyretic, and attenuation of eicosanoid production properties are favorable.  Examples of NSAIDs 
that are often used in the horse include phenylbutazone (Bute®), flunixin meglumine 
(Banamine®), firocoxib (Equioxx®), and ketoprofen (Ketofen®).  All of the above medications 
have labels supporting their usage in the treatment of osteoarthritis or other musculoskeletal 
disorders. 
In the horse, the pharmacokinetics of the oral and intravenous formulations of the 
commonly used NSAIDs have been investigated thoroughly; however, the pharmacokinetics of 
meloxicam have only been investigated for the intravenous and oral suspension formulations of 
the drug.  In the United States, both formulations would be financially prohibitive, resulting in 
costs of over $200.00 a day.  Although off label, the use of oral tablets would result in a cost of 
approximately $2.00 per day.  This is between the average cost of phenylbutazone and firocoxib 
(Equioxx®) (approximately $0.40 and $9.00 per day, respectively).  In addition, due to its 
potential cyclooxygenase isoform selectivity, meloxicam may result in fewer gastrointestinal and 
renal adverse effects compared to the more commonly used NSAIDs. 
It was the purpose of this investigation: 
a.  To determine the disposition and adverse effects of oral meloxicam tablets 
following administration of a single dose and daily doses over 14 days. 
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b. To ascertain the analgesic effects of meloxicam on lame horses and compare 
to the effect of phenylbutazone in natural lameness and lipopolysaccharide-
induced synovitis models. 
c.  
a. To evaluate the effects of incubation of equine PBMCs with LPS ex 
vivo to determine the level of cyclooxygenase-2 upregulation. 
b. To evaluate the effects of local injection of LPS into the 
metacarpophalangeal joint on the level of cyclooxygenase-2 protein 
expression in equine PBMCs and effect of orally administered 
phenylbutazone or meloxicam using qRT-PCR. 
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Chapter 2 - Literature Review 
 Pharmacokinetics 
 Introduction 
Pharmacokinetics deals with the mathematical description of the time course of drug 
absorption, distribution, and elimination by means of a suitable model (Levy 1972).  This 
discipline has allowed dosages of drugs to be tailored to both individuals and groups to optimize 
therapeutic effectiveness and minimize toxicity and adverse events. 
To facilitate the study of the pharmacokinetic behavior of drugs, the body is depicted as a 
system made up of one, two, or three distribution compartment open models (Figures 2.1, 2.2, 
2.3).  The principle adopted in analyzing the serum-concentration time profiles is to employ the 
pharmacokinetic model with the least number of compartments that can adequately describe the 
data.   
If a drug distributes very rapidly relative to the rate of elimination, the disposition 
kinetics of the drug behaves as a single homogenous distribution and the one-compartment open 
model is applied (Figure 2.1).  This model assumes that a change in the drug concentration in 
one tissue is accompanied by a corresponding change in drug concentration in all other tissues 
(including plasma) at the same time.  The following expression satisfies the one-compartment 
open model (Baggot 1977): 
 
Cp = Be-βt                                                                                              (1) 
 
where Cp is the concentration of the drug in plasma at any time, t; B (µg/mL) is the zero-time 
intercept extrapolated from the overall elimination rate constant, β; and e is the base of the 
natural logarithm. 
 It is assumed that a drug that is introduced into the central compartment, which consists 
of blood plasma and the extracellular fluid of highly perfused organs such as kidneys, lungs, 
liver, and heart, distributes instantaneously and homogeneously and that it is eliminated 
exclusively from the central compartment.  Distribution into the second or peripheral (tissue) 
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compartment, which consists of less perfused tissues such as muscle, skin, and body fat, occurs 
more slowly.  A two-compartment open model (Figure 2.2) can be described by the following 
expression: 
 
Cp = Ae-αt + Be-βt                                                                                         (2) 
 
where Cp is the concentration of the drug in the plasma at any time, t; A and B (µg/mL) are 
extrapolated intercepts; α and β are the rate constants for the distribution and elimination phases 
respectively; e represents the base of the natural logarithm.  The sum of A and B (µg/mL) gives 
the plasma concentration at time zero. 
The three-compartment open model (Figure 2.3) can be described by the following 
expression: 
 
Cp = Pe-πt + Ae-αt + Be-βt                                                    (3) 
 
where Cp is the concentration of the drug in the plasma at any time, t; P, A, and B (µg/mL) are 
zero-time extrapolated intercepts respectively; π and α are the rate constants of distribution 
phases; β is the rate constant of the elimination phase; and e is the base of the natural logarithm. 
 The rate constants of the absorption and elimination of the drug are assumed to follow 
first-order kinetics, i.e., a constant fraction of the drug present is eliminated per unit time 
(Goodman 1975).  The elimination of most drugs is exponential since drug concentrations 
usually do not approach those required for saturation of the elimination process.  Suitable dosage 
regimens for drugs exhibiting dose-dependent kinetics in the therapeutic range defy easy 
calculation and are only established by careful titration of drug level in the patient (Levy 1968). 
 In certain exceptional cases, the drug elimination processes may become saturated and 
the result is zero-order kinetics, i.e., a constant amount of the drug is eliminated per unit time.  
An increase in dosage results in a more prolonged half-life and a disproportionately greater 
accumulation of the drug in the body (Goodman 1975).  The elimination of phenylbutazone in 
the dog (Dayton 1967) and in the horse (Piperno 1968) obeys zero-order kinetics.  The rate of 
elimination of a drug may be influenced by extensive binding to plasma protein, the rate of 
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various metabolic pathways, and the efficiency of excretion processes, particularly glomerular 
filtration (Baggot 1977). 
 Principles of pharmacokinetic analysis 
 
Intravenous (IV) injection is the most reliable method of administration of a drug for the 
purpose of pharmacokinetic analysis.  The biexponential equation, 
 
Cp = Ae-αt + Be-βt                                                                                         (4) 
 
describes the decline of a drug concentration-time curve after IV of a single bolus dose.  The 
biexponential expression of the two-compartment open model assumes that, when injected IV, 
the drug distributes instantaneously throughout the central compartment.  The initial steep 
decline in plasma concentration of a drug is due to the distribution of the drug by passive 
diffusion from the central to the peripheral compartment.  Once apparent distribution equilibrium 
is attained, the rate of decline in plasma drug concentration is decreased and the linear terminal 
phase is referred to as the β or the elimination phase.  Iterative least squares linear regression 
analysis is used to find the best fit curve.  The slope of the linear terminal portion of the curve 
may be defined as –β/2.303 and an extrapolation of this line gives the zero-time intercept, B 
(µg/mL), which is an estimate of the drug concentration that would have been attained if the 
distribution were instantaneous. 
 The residual data points, representing α (the distribution phase), are obtained by 
subtracting the extrapolated portion of β (the elimination phase) from the experimental data of 
the initial steep portion of the concentration-time curve.  Least squares regression analysis for the 
residual data is used to obtain the best fit curve of the distribution phase (α) and extrapolation of 
this line yields zero-time intercept, A. 
 For the three-compartment open model, the second set of residual data points are 
obtained by subtracting the extrapolated portion of the first distribution phase from its steep 
portion.  Least squares regression analysis for the second set of residual data is used to obtain the 
best fit curve of the second distribution phase, π.  The extrapolation yields the zero-time 
intercept, P (µg/mL).
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 Pharmacokinetic parameters 
 Pharmacokinetic rate constants 
The plasma drug concentration-time curve provides the only accurate information for 
drug measurement in the body.  The experimental constants (A, B, α, or β) are “hybrid” 
pharmacokinetic parameters and are used to calculate the actual pharmacokinetic rate constants 
(k12, k21, and kel) associated with the two-compartment open model. 
 
BA
BαAβk12
+
+
=                                                             (5)   
 
k21 = α + β – k21 – kel                                                                                  (6) 
 
are the rate constants for distribution between central and peripheral compartments, and 
 
21
el
k
αβk =                                                                   (7) 
 
is the rate constant for elimination.  All of these expressions are given in units of reciprocal time 
(h-1). 
 Determination of the microconstants allows an assessment of the relative contribution of 
distribution and elimination processes (which may be altered in diseased states) to the 
concentration-time profile of a drug (Baggot 1977).  A computer program, using values of the 
individual rate constants of the model, can be used to predict curves which describe the levels of 
a drug (expressed as a fraction of a single dose) in the central and peripheral compartments as a 
function of time, as well as the elimination curve.  Based on the hybrid and actual 
pharmacokinetic parameters, other parameters associated with the two-compartment model can 
be calculated. 
 Volume of distribution 
The volume of distribution is defined as the volume of fluid which would be required to 
contain the amount of drug in the body if it was uniformly distributed at a concentration equal to 
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that in plasma.  The body is assumed to behave as a single homogenous compartment with 
respect to the drug.  The value of Vd serves as a proportionality constant relating the plasma 
concentration of the drug to the amount in the body at any time after distribution equilibration 
has been attained.  Vd is expressed as, 
 
(mg/mL) ionconcentrat
(mg) mass(mL) Vd =                                                 (8) 
 
The calculation of its value will be dependent on the modeling scheme utilized.  Multiple 
physiological and protein-binding properties change the nature of the concentration profile being 
modeled and can change the value of Vd obtained. 
 Half-life 
The half-life for the elimination phase or the biological half-life of a drug is defined as 
the time required for the body to eliminate half of a particular drug, i.e., the time it takes for the 
serum concentration of the drug to decrease by 50% during the elimination phase of the 
disposition curve.  It is assumed that, once pseudodistribution equilibrium has been established, 
the ratio of the drug in peripheral to central compartments remains constant.  The half-life value 
is obtained from the equation,  
 
β
0.693t1/2 =                                                                     (9) 
 
Where β is the overall elimination rate constant and t1/2 is expressed in units of time (h).  An 
estimate of the half-life may also be obtained graphically.  A large value of β corresponds to a 
short half-life and indicates rapid elimination (Baggot 1977). 
 For drugs that obey zero-order kinetics, their half-lives become progressively longer as 
the doses increase (Baggot 1978).  Knowledge of the half-life is a very useful for design of 
rational dosage regimens. 
 The half-lives of most drugs are independent of the dose and route of administration.  
Intravenous injection of a single dose of the drug is the only satisfactory procedure to determine 
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the half-life value since the apparent overall rate of elimination following other routes may be 
influenced by the rate of absorption (Byron 1976). 
 Mean absorption time 
Mean absorption time (MAT) is the mean of the arrival time of bioavailable drug into 
systemic circulation.  It is the statistical moment theory equivalent of estimating ka and is a 
relatively straightforward method to characterize the rate of absorption in bioavailability studies. 
 
MAT = MRTni – MRTIV                                                  (10)  
 
MAT is the difference in mean residence time (MRT) following IV injection (MRTIV) and the 
MRT by any other route (MRTni). 
 Bioavailability 
The extent and rate of absorption after oral, topical, or inhalational drug administration is 
referred to as the bioavailability, F.  To estimate the amount of drug that would normally be 
found if the entire dose were absorbed, an intravenous dose would be required, as this is the only 
route of administration that guarantees 100% of the dose is systemically available (F = 1.0) and 
the pattern of disposition and metabolism can be quantitated.  For most drug studies, absorption 
is measured using blood concentrations.  When drug concentrations in plasma are assessed, the 
measure of the area under the concentration-time curve (AUC) is used to estimate total 
absorption.  Absolute systemic availability is calculated as 
 
route iv
iv route
Dose *AUC
Dose* AUC(%) F =                                                     (11) 
 
Calculation of F only gives an estimate of the extent, not the rate, of absorption. 
 
Accumulation ratio 
 When multiple doses are given, the drug accumulates until the plasma concentration is 
large enough for elimination to balance absorption.  Accumulation from one dose to the next is 
significant when the next dose is given before most of the previous dose has been eliminated.  
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The accumulation ratio, AR, is stated as the ratio of the average concentration at steady state to 
the average concentration during the first dose interval and is calculated by the equations, 
 
     
             (12) 
 
CL*AUC
CL* AUCAR
 1
 ss
=
   
 Non-steroidal anti-inflammatory drugs 
Non-steroidal anti-inflammatory drugs exert their activity by blocking the 
cyclooxygenase-driven conversion of arachidonic acid to the prostanoids such as thromboxane 
and the prostaglandins (Figure 1).  There are two commonly recognized isoforms of 
cyclooxygenase (formerly known as prostaglandin endoperoxide synthase (Vane 1998)): 
isoform 1 (COX-1) and isoform 2 (COX-2).  COX-3 is a recently described isoform that is 
encoded by the same gene as COX-1; however, COX-3 retains an intron that is not retained in 
COX-1.  It is not functional in humans and has not yet been studied in the equine species and 
therefore will not be discussed further. 
The COX-1 isoform, discovered in 1976 (Hemler), is responsible for the production of 
prostaglandin E2 (PGE2), thromboxane A2 (TxA2), and prostaglandin I2 (PGI2).  It is 
constitutively produced in most tissues and produces prostanoids that are essential for normal 
physiologic processes, such as platelet aggregation, gastrointestinal protection, and perfusion and 
electrolyte balance in the kidney. 
The COX-2 isoform was discovered in 1991 and it converts arachidonic acid into the 
prostanoids PGE2 and PGI2.  It is not expressed in most cells under normal conditions, but is 
rapidly inducible as a result of damaging stimuli from cytokines, growth factors, and bacterial 
toxins present at inflammatory sites, in infection, and in neoplasia.  This isoform is responsible 
for producing prostaglandins that amplify shock, inflammation, and pain (Ferraz 1997). 
In the first step of prostanoid synthesis, the cyclooxygenase activity of either COX-1 or 
COX-2 oxygenates and isomerizes arachidonic acid, creating the intermediate product 
prostaglandin G2 (PGG2) (Figure 2.4).  In the second step, which occurs as a different 
1 av,
ss av,
C
CAR =
(13) (13) 
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enzymatic site, peroxidase reduces PGG2 to its hydroxyl analog, PGH2.  Distinct synthases or 
reductases then convert PGH2 to one of several stable prostanoids:  PGD2, PGE2, PGF2α, PGI2, or 
TxA2 (Smith 1996). 
The molecular structures of COX-1 and COX-2 show that both isoforms are dimers, with 
the COX activation site located in a long, hydrophobic channel between the two subunits (Figure 
2.5).  A substitution of one amino acid in the activation site, from isoleucine in COX-1 to valine 
in COX-2, creates a second, larger NSAID-binding pocket; it is this additional binding site that 
confers selectivity of NSAIDs for one isoform or the other (Kurumbail 1996).  Smaller NSAIDs 
can bind to the pocket in the activation sites of either COX-1 or COX-2; the larger COX-2-
specific inhibitors only fit into the larger binding pocket found on the COX-2 isoform. 
Selective inhibition of COX-1 leads to the gastrointestinal toxicity associated with the use 
of NSAIDs.  Prostaglandins function to regulate motility, secretion, blood flow, and mucosal 
cytoprotection and inhibition of these functions leads to gastrointestinal ulceration.  In small 
animal medicine, the use of the COX-2 selective inhibitors (carprofen, etodolac) has reduced the 
occurrence of GI side effects; however, there is a paucity of published data on these substances 
in horses.  Drugs such as phenylbutazone and flunixin meglumine continue to be the mainstay of 
NSAID therapy.  In one report, phenylbutazone was associated with greater toxicity than flunixin 
meglumine (MacAllister 1993).  In a study combining flunixin meglumine and phenylbutazone 
at regular doses (1.1 mg/kg IV q 12 h for 5 days and 2.2 mg/kg PO q 12 h for 5 days, 
respectively), one horse died acutely due to acute necrotizing colitis, with lesions most severe in 
the right dorsal colon (Keegan 2008).  The horse had recently completed the combination 
therapy portion of the study.  The same group performed the study two years prior and, in that 
study, one horse was euthanized with severe hypoproteinemia, hypoalbuminemia, and colitis 
after only 5 days of combination therapy.  The horse was euthanized on day 7 of the study for 
severe colic, unresponsive to analgesic medications (Reed 2006). 
Renal complications of NSAIDs are also related to the inhibition of basal prostaglandin 
production.  Hypovolemia, congestive heart failure, chronic renal insufficiency, sepsis, and 
anesthesia are common conditions that lead to increased vasoconstrictor activity in the kidney.  
Angiotensin, norepinephrine, and vasopressin lead to reduced renal blood flow and result in a 
feedback loop causing a release of prostaglandins.  This causes vasodilation and a return to 
normal renal blood flow and glomerular filtration.  Prostaglandins have regulatory functions at 
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the tubular level.  NSAIDs lead to reduced blood flow, hyperkalemia secondary to suppression of 
renin and aldosterone secretion, increased sodium, chloride, and water reabsorption, and causes 
renal papillary necrosis secondary to medullary ischemia.  Used at clinically relevant doses in 
healthy patients, the incidence of adverse events is low; however, even mild dehydration can 
result in dramatic detrimental effects. 
Most NSAIDs block both COX-1 and COX-2 to some degree, but some of the newer 
drugs, such as meloxicam, are reported to be more selective against the COX-2 enzyme.  As the 
use of non-selective NSAIDs (those that block both COX-1 and COX-2) has been associated 
with gastrointestinal ulceration (including right dorsal ulcerative colitis) (Karcher 1990, Galvin 
2004, McConnico 2008, Marshall 2011) and renal papillary necrosis in equines (MacKay 1983, 
Gunson 1983a/b, Read 1983, Collins 1984, Faulkner 1984, Black 1986), use of selective 
inhibitors may be associated with a decreased incidence of these adverse effects.  However, it is 
important to note that compounds that are highly selective COX-2 inhibitors in one species may 
not necessarily exert the same selectivity in other species.  Highly selective COX-2 inhibitors in 
humans have been associated with severe liver and cardiovascular side effects, probably in 
relation to highly reduced anti-COX-1 activity (Ferreiro 2000; Schattner 2000; Topol 2004). 
In 1998, a classification system was developed (Lipsky 1998).  According to this system, 
COX inhibitors can be considered to belong to one of four groups:  (1) COX-1-specific inhibitor: 
an agent with no measurable inhibition of COX-2.  Low-dose aspirin is the only drug that fits 
into this category; (2) COX-nonspecific inhibitor:  inhibits both COX-1 and COX-2, perhaps 
with small pharmacologic differences in activity between the two isoenzymes, but with no 
clinically relevant differences in specificity; (3) COX-2-preferential inhibitor:  inhibits COX-2 
with little COX-1 inhibition at therapeutic dosages; (4) COX-2-specific inhibitor:  agents that 
produce no clinically significant inhibition of COX-1, even at the highest therapeutic dosages. 
 Meloxicam 
Meloxicam, an enolic acid in the oxicam class, is similar in structure to sudoxicam and 
piroxicam.  It is intended to be administered intravenously or orally to horses for the treatment of 
inflammatory conditions, particularly orthopedic disorders.  It is approved for use in humans, 
dogs, and cats in the United States and is approved for use in the horse in Europe and other 
countries.  There has been a recent boom in investigations of meloxicam as an analgesic and 
12 
 
anti-inflammatory in rats, goats, mice, dogs, and cats undergoing orthopedic procedures or injury 
(Bourque 2010; Goodman 2010; Ingvast-Larsson 2010; Keita 2010; Murison 2010; Gruet 2011; 
Hakan 2011; Hicks 2011; Morton 2011; Tubbs 2011).  Currently, there is no approved 
formulation of meloxicam for use in the horse in the United States. 
The pharmacokinetics of meloxicam were first investigated in ponies in 1991 (Lees 
1991).  In this study, ponies were injected with 0.6 mg/kg meloxicam intravenously                                                                                                                                                                         
(then named “miloxicam”) and pharmacokinetic variables were measured over 24 hours.  In the 
same study, the actions of meloxicam were compared to placebo in a carrageenan-sponge model 
of inflammation.  In five of the ponies, the plasma-time concentration curve was defined as a 
two-compartment model.  In one pony, a three-compartment model was defined.  The results of 
the pharmacokinetic investigation are listed in Table 1.1.  In unpublished investigations by the 
manufacturer, the half-lives of meloxicam were evaluated in multiple species (Table 1.2).  
Another investigation evaluated the pharmacokinetics of the oral suspension of meloxicam 
(Metacam® oral suspension, Boehringer Ingelheim, Vetmedica) and compared the bio-
availability between fed and non-fed horses (Toutain 2004a) and found that the bioavailability 
was not significantly different, however the mean absorption time was longer in fed horses.  The 
pharmacokinetic-pharmacodynamic relationships and dose response was evaluated in horses 
using an induced arthritis model using Freund’s adjuvant (Toutain 2004b).  In this study, 
increasing doses of meloxicam (from 0 to 2.0 mg/kg) were administered intravenously and stride 
lengths and clinical lameness scores were used to assess the effect of the drug.  This study 
suggested that a dose of 0.6 mg/kg would be an effective dose for clinical use in horses.  The 
pharmacokinetics of meloxicam was determined again in adult horses and donkeys using the 
intravenous formulation (Sinclair 2006).  The investigators found an extremely short mean 
residence time (MRT) and total body clearance (CLT) in donkeys compared to horses, 
indicating that its use may be impractical in this species.  The pharmacokinetic variables of the 
oral suspension of meloxicam have also been determined in foals less than 6 weeks of age and no 
adverse effects were noted (Raidal 2009). 
Plasma pharmacokinetic data can be problematic when determining dosing intervals with 
non-steroidal anti-inflammatory drugs.  For instance, phenylbutazone and flunixin meglumine 
block the synthesis of eicosanoids such as PGE2 for 12-24 hours when administered 
intravenously, but their elimination half-lives are short (4.7-6.1 h and 1.6-1.9 h, respectively) 
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(Tobin 1979; Lees 1987).  Studies that have examined pharmacodynamic features of meloxicam 
have indicated that, although the drug has a relatively short half-life and mean residence time, 
once daily dosing is feasible because it reversibly inhibits eicosanoids in inflammatory exudates 
between 4 and 24 hours after dose administration (Lees 1991).  A short MRT and long clearance 
from inflammatory exudates is similar in the other acidic NSAIDs such as phenylbutazone and 
flunixin meglumine.  Mean residence time is a non-compartmental variable that is based on 
statistical moment theory and is analogous to half-life calculations in compartmental analyses.  
However, pharmacokinetic and statistical studies have found that MRT is often greater than half-
life, especially if the drug is defined by a two compartment model.  Regardless, the clinical 
usefulness of the drug is often determined by its median effective dose (ED50).  The ED50 is a 
variable related to formulation or route of administration.  It is the dose of the drug at which 50% 
of Emax is achieved and is a measure of drug potency. 
The median effective dose of the drug was calculated in one study using a Freund’s 
adjuvant-induced synovitis (Toutain 2004b).  The overall ED50 for lameness score at three 
selected time points (4, 6, and 8 hours) was 0.265 mg/kg.  However, 0.617 mg/kg was calculated 
as the overall dose at 70% of the maximum possible effect for clinical lameness scores.  This 
coincides with other studies that have determined that the appropriate dose is 0.6 mg/kg.  
Because the study concluded that intravenous meloxicam was an efficacious anti-inflammatory 
and analgesic drug in horses with experimentally induced arthritis, a similar model was chosen in 
this study to evaluate the effect of the oral formulation. 
The EC50, or median effective concentration, was also calculated by Toutain, et al 
(2004b).  In that study, the overall EC50 for lameness score was 195 ng/mL and was calculated at 
the point in which 70% of the lameness was suppressed.  This EC50 can be used for any 
meloxicam formulation and other routes of administration by transforming into the 
corresponding ED50 by multiplying the EC50 by the plasma clearance for the IV route or an 
apparent plasma clearance (i.e., clearance divided by bioavailability) for an extravascular route 
of administration. 
Mean absorption time (MAT) was calculated in one study (Toutain 2004a) and found to 
vary between 2.07 to 6.32 hours (mean 3.62 ± 1.39 hours).  The MAT after the first dose for 6 of 
8 fed horses was significantly higher than the MAT obtained in non-fed horses.  This would 
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suggest that the physiologic status of the gastrointestinal tract may slow the rate of absorption 
after oral administration but, in this study, did not affect the bioavailability. 
 Meloxicam is intended for multiple administrations.  With respect to bioavailability, 
Toutain, et al (2004b), found that there was no difference between the first and last dose in a 14 
day study.  The accumulation ratio was low in that study (1.08 ± 0.111), which suggests that 
steady-state concentration was reached immediately. 
 Meloxicam has been evaluated for its effectiveness in lameness models, both in vitro and 
in vivo.  The efficacy of NSAIDs in inflammatory joint disease is largely attributed to their 
inhibition of COX-mediated production of PGE2 within the joint space.  Additionally, NSAIDs 
have demonstrated effects on cytokine release (Rainsford 1997; Bianchi 2007), proteoglycan 
turnover (Rainsford 1997; Blot 2000), as well as on matrix metalloproteinase (MMP)-activity 
(Chu 2008).  In vitro suppression of MMP activity has also been reported for meloxicam 
(Barracchini 1998, 1999; Sadowski 2001).  In vitro, synovial explants have been used to evaluate 
the anti-inflammatory effects of meloxicam in an LPS challenge model (Moses 2001).  Synovial 
explants were prepared and treated with several NSAIDs including phenylbutazone, flunixin 
meglumine, meloxicam, etc.  In this study, meloxicam was shown to significantly decrease PGE2 
concentrations when compared to the other NSAIDs in LPS-challenged explants.  This was 
confirmed in vivo in 6 horses with LPS-induced synovitis (deGrauw 2009a).  Prostaglandins, 
especially PGE2, are potent mediators of joint inflammation and occur naturally in osteoarthritic 
joints and are responsible for the clinical signs associated with osteoarthritis (Dayer 1986; 
Tawara 1991; May 1992; Knott 1993; Knott 1994).  Early use of meloxicam has been shown to 
ameliorate clinical signs and inflammation in acute synovitis and may also limit inflammation-
induced cartilage catabolism (deGrauw 2009a). 
There has been much discussion about whether meloxicam is a selective inhibitor of 
COX-2.  In the rat, using pleurisy and peritonitis models, meloxicam significantly reduced PGE2 
concentrations over piroxicam, diclofenac, and tenidap (Engelhardt 1996).  The concentration 
required to inhibit 50% of COX activity (IC50) has been determined in dogs by the use of a 
whole blood assay.  The ratio of IC50 for COX-1 to the IC50 of COX-2 for meloxicam was 10 
(Brideau 2001).  Another study was performed to compare the effects of phenylbutazone, 
flunixin meglumine, meloxicam, and carprofen on thromboxane B2 (TxB2) and PGE2 
concentrations in blood incubated with LPS (Beretta 2005).  The values of TxB2 were used as a 
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measure of COX-1 activity and the values of PGE2 were used as a measure of COX-2 activity.  
Using concentration response curves, concentrations producing 50% (IC50) and 80% (IC80) 
inhibition for each NSAID were evaluated.  Selectivity at 50% and 80% inhibition was 
calculated as IC COX-1/IC COX-2.  At 50% inhibition, flunixin had the strongest anti-COX-1 
activity while meloxicam had the strongest anti-COX-2 activity.  When the four NSAIDs were 
examined for COX-1 inhibition at concentrations producing 80% inhibition of COX-2, COX-1 
inhibition was 70.97% for meloxicam, 72.58% for carprofen, 79.59% for phenylbutazone, and 
83.81% for flunixin meglumine.  Unfortunately, the debate cannot be settled using in vitro 
inhibition assays as, even in human whole blood assays, minor variations in conditions leads to 
different IC50 ratios of 2.71 and 24.78 in a single laboratory (Warner 1999). 
Evidence for the COX-2 selectiveness of meloxicam was further suggested in a study 
evaluating the effect of meloxicam on ischemic jejunum as compared to the effect of flunixin 
meglumine (Little 2007).  In this study, 18 horses were subjected to general anesthesia and the 
jejunum placed under ischemic conditions for 2 hours.  The horses were administered saline 
solution (control), flunixin meglumine, or meloxicam (0.6 mg/kg IV) one hour prior to the 
ischemic event.  After recovery from anesthesia, the horses were monitored for 18 hours then 
euthanized and samples of the jejunum were submitted for histopathology and Ussing chamber 
studies.  COX-1-elaborated prostaglandins are necessary for proper recovery of intestinal barrier 
function and meloxicam appears to mainly inhibit the detrimental effects of COX-2-elaborated 
prostaglandins.  The results of the study indicate that meloxicam did not impede recovery of 
ischemia-injured jejunum and may be considered for analgesia and endotoxemia associated with 
colic. 
 Synovitis models 
In horses, intra-articular lipopolysaccharide (LPS) injection is an established model for 
induction of sterile, transient synovitis and allows the study of clinical symptoms and therapeutic 
efficacy (Firth 1987; Palmer 1994; Morton 2005; Meulyzer 2008; deGrauw 2009a).  LPS allows 
for a reversible, non-septic inflammation of a joint sufficient to cause temporary lameness 
without severe systemic or long-term side effects.  The inflammatory markers and cartilage 
biomarkers in synovial fluid were evaluated after a single dose of intra-articular LPS (deGrauw 
2009b).  The LPS injection led to a sharp rise in PGE2 at 8 hours post-injection, and substance P, 
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bradykinin, and MMP activity were increased at 8 and 24 hours after injection.  Equine articular 
chondrocytes, when exposed to inflammatory stimuli, increase PGE2 concentrations and 
upregulate COX-2 expression (Farley 2005).  Meloxicam has been shown to influence synovial 
fluid prostaglandin E2, substance P, bradykinin, and MMP activity in the first 24 hours after 
injection of LPS (deGrauw 2009a).  In addition to attenuation of synovial fluid PGE2, substance 
P, and bradykinin concentrations, meloxicam significantly improved lameness scores compared 
with those of placebo. 
The penetration of NSAIDs into synovial compartments depends on the chemical 
characteristics of the compound but usually reaches approximately 60% of the mean plasma 
concentration because of low protein concentrations within synovial fluid.  Penetration may 
increase in the presence of synovitis and synovial fluid concentration in inflamed joints often 
exceeds plasma concentrations because of accumulation and binding of proteins.  In one study, 
intra-articular ketoprofen concentrations in horses with acute synovitis were 6.5 times higher 
than those in healthy horses (Owens 1995). 
 Lameness Grades 
The American Association of Equine Practitioners (AAEP) has developed a grading 
system to standardize the evaluation of lame horses.  The grading scheme is as follows: 
0: Lameness not perceptible under any circumstances.  
1: Lameness is difficult to observe and is not consistently apparent, regardless of 
circumstances (e.g. under saddle, circling, inclines, hard surface, etc.).  
2: Lameness is difficult to observe at a walk or when trotting in a straight line but 
consistently apparent under certain circumstances (e.g. weight-carrying, circling, inclines, 
hard surface, etc.).  
3: Lameness is consistently observable at a trot under all circumstances.  
4: Lameness is obvious at a walk.  
5: Lameness produces minimal weight bearing in motion and/or at rest or a complete 
inability to move. 
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 Figures and Tables  
 
Table 2.1 Comparison of pharmacokinetic studies of intravenous and oral suspension 
formulations of meloxicam. 
PK Parameter Lees 1991 Toutain 2004 Toutain 2004 Sinclair 2006 
Formulation IV Oral suspension IV IV 
Vd 0.158 L/kg 0.12 ± 0.018 0.23 0.24 ± 0.16 
Clβ 41.87 mL/kg/h 34 ± 5.7 81.0 34.7 ± 9.21 
AUC 14.53 ± 0.8 µg/mL/h   18.8 ± 7.31 
Bioavailability  98 ± 12% fed 
85 ± 19% non-fed 
  
 
Table 2.2  Comparison of half-lives of oral and intravenous meloxicam formulations in 
different studies. 
Species Dose Half-life Reference 
Cow 0.2, 0.5 mg/kg IM 13 h Boehringer-Ingelheim, unpublished 
Rat 0.3 mg/kg IV 11.3 h Boehringer-Ingelheim, unpublished 
 30.0 mg/kg IV CRI 9.4 h Boehringer-Ingelheim, unpublished 
Miniature pig Unknown 4 h Boehringer-Ingelheim, unpublished 
Man Variable 20-50 h Boehringer-Ingelheim, unpublished 
Dog Variable 12-36 h Boehringer-Ingelheim, unpublished 
Horse 0.2 mg/kg IV 1.9 h Boehringer-Ingelheim, unpublished 
 0.5 mg/kg IV 2.1 h Boehringer-Ingelheim, unpublished 
 0.6 mg/kg IV 2.7 h Lees 1991 
 0.6 mg/kg oral susp 8.54 ± 3.02 h Toutain 2004a 
 0.6 mg/kg IV 5.15 h Toutain 2004b 
 0.6 mg/kg IV 9.6 ± 9.24 h* Sinclair 2006 
*Mean Residence Time 
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Figure 2.1 One compartment open pharmacokinetic model with first-order absorption. 
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Figure 2.2 Generalized open two-compartment pharmacokinetic model with first-order 
absorption (K01) into and elimination (Kel) from the central compartment.  K12 and K21 represent 
intercompartmental micro-rate constants. 
 
 
 
 
 
 
 
Figure 2.3  Three-compartment pharmacokinetic model after intravenous administration. 
 
 
 
 
 
 
 
 
Ka 
Vd 
Kel 
Central 
(1) 
Peripheral 
(2) 
Kel = K10 
K01 = Ka 
Central 
(1) 
Peripheral 
(2) 
K01 = Ka 
Kel = K10 
⎯⎯→⎯
12K
⎯⎯ ⎯←
13K
⎯⎯ →⎯
31K
⎯⎯ ⎯←
21K
Peripheral 
(3) 
19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 The arachidonic acid cascade.  HPETE = hydroperoxyeicosatetraenoic acid; HETE = 
hydroxyeicosatetraenoic acid; LT = leukotriene. 
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Figure 2.5  COX-1 and COX-2 substrate-binding channels. Schematic depiction of the structural 
differences between the substrate-binding channels of COX-1 and COX-2 that allowed the 
design of selective inhibitors. The amino acid residues Val434, Arg513, and Val523, form a side 
pocket in COX-2 that is absent in COX-1. A, Nonselective inhibitors have access to the binding 
channels of both isoforms. B, The more voluminous residues in COX-1, Ile434, His513, and 
Ile532, obstruct access of the bulky side chains of the coxibs.  (From Grosser T, Fries S, 
FitzGerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: 
Therapeutic challenges and opportunities. J Clin Invest 116:4-15, 2006.)   
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Chapter 3 - Materials and Methods 
All procedures were approved by Kansas State University Institutional Animal Care and 
Use Committee. 
 Aim 1 
 Experimental design and sample collection 
Sixteen horses of mixed breeds, 14 owned by the University and 2 client-owned animals, 
were evaluated via gastroscopy for the presence of gastric ulcers prior to entrance to the study.  
The horses were fasted for 12 hours prior to the examination and water was withheld for 3 hours.  
The horses were sedated with xylazine hydrochloride (0.5 mg/kg IV) and butorphanol (0.01 
mg/kg IV) or with detomidine (0.01 mg/kg IV) and butorphanol (0.01 mg/kg IV), depending on 
the nature and temperament of the horse.  Each was placed in stocks and restrained normally.  
Gastric ulcer scoring was performed by two investigators.  If the horses had grade 2 ulcers or 
below, the horse was included in the study and complete blood count, serum biochemistry, and 
urinalysis was performed the following day.   
The animals that participated in the study were housed in 12 x 12 stalls in a climate 
controlled environment.  They were fed free choice brome and alfalfa hay and 3 pounds of 
equine Strategy or equine Senior (Purina) twice daily, depending on age.  Free choice fresh water 
was available at all times.  Each horse was weighed with a commercial scale prior to the 
beginning of the study and an intravenous catheter (14 g, 5.25 inch Abbocath™, Abbott 
Laboratories, Abbott Park, IL) was placed in the left jugular vein using aseptic technique.  A 
baseline blood sample was taken via the jugular catheter and placed into a heparinized tube 
(green top).  Meloxicam (15 mg tablets, Caraco Pharmaceutical Labs, Detroit, MI) was 
administered to each horse at 0.6 mg/kg orally once daily for fourteen days.  The tablets were 
crushed and mixed with 15 mL of molasses and given via dosing syringe in the morning.  Blood 
sampling for pharmacokinetic analysis was performed at 20 and 40 minutes, and at 1, 2, 4, 8, 12, 
and 24 hours after administration of the tablets.  The intravenous catheter was removed after 24 
hours and the horses were returned to their normal environment.  This was repeated and blood 
samples were taken on days 7 and 14.  Trough samples were taken via direct venipuncture on 
days 4 and 10 while in their natural environment.  All blood samples were centrifuged for 5 
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minutes at 3700 g and the plasma was removed and frozen at -80ºC until analysis could be 
performed. 
At the conclusion of the study, repeat complete blood count, serum biochemistry, 
urinalysis, and body weight was performed.  Additionally, the horses were fasted and a 
gastroscopy under IV sedation as noted above was performed to evaluate gastric ulcer scores. 
Sample analysis 
Plasma concentrations of meloxicam (m/z 352.09→114.90) were determined with high-
pressure liquid chromatography (Shimadzu Prominence, Shimadzu Scientific Instruments, 
Columbia, MD, USA) and mass spectrometry (API 2000, Applied Biosystems, Foster City, CA, 
USA). Plasma samples or standards (100 µL) were added to 100 µL of internal standard 
(piroxicam 0.5 µg/mL in methanol, m/z 332.12→95.10) and 300 µL of methanol with 0.1% 
formic acid to precipitate the proteins.  The samples were vortexed for 5 seconds and centrifuged 
for 10 minutes at 10,000 x g.  The supernatant, 200 µL, was transferred to an injection vial with 
the injection volume set to 10 µL. The mobile phase consisted of A: acetonitrile and B: 0.1% 
formic acid at a flow rate of 0.4 mL/min. The mobile phase consisted of 85% B from 0 – 0.5 
minutes with a linear gradient to 50% B at 2.5 minutes which was maintained until 3 minutes, 
followed by a linear gradient to 85% B at 4 minutes with a total run time of 5 minutes. 
Separation was achieved with a C8 column (Supelco Discovery C8, 50 mm x 2.1 mm x 5 µm, 
Sigma-Aldrich, St. Louis, MO, USA) maintained at 40° C. The standard curve was linear from 
0.01 µg/mL to 10 µg/mL and was accepted if the correlation coefficient exceeded 0.99 and 
predicted values were within 15% of the actual values.  
 Statistical analysis 
Pharmacokinetic analyses were performed with computer software (WinNonlin 5.2, 
Pharsight Corporation, Mountain View, CA, USA).  The variables calculated included the area 
under the curve (AUC) using the linear trapezoidal rule, maximum serum concentration 
(CMAX) and time to maximum serum concentration (TMAX) obtained directly from the plasma 
concentration data.  Pharmacokinetic parameters on days 1, 7, 14 were compared for difference 
using a repeated measures analysis of variance.  Paired t tests were used to compare pre- and 
post-administration white blood cell counts, total serum protein measurements, creatinine levels, 
and gastric ulcer scoring.  Repeated measures ANOVA was used to evaluate differences between 
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days 0, 7, and 14 for volume of distribution, clearance, area under the curve, half-life, and mean 
residence time.  All tests were considered statistically significant with a P value <0.05. 
 Aim 2 
For the second aim of the study, four horses were evaluated via physical examination, 
body weight, complete blood count, serum biochemistry, and urinalysis.  Gastroscopy was 
performed as described above but there were no restrictions on level of gastric ulceration for 
inclusion in the study.  The only restriction placed on the acquisition of the horses was that they 
had not received NSAID medications within the last 6 months.  The horses were donated to the 
University because of their lameness, attributed to chronic laminitis as evidenced by 
characteristic abnormalities of their hoof walls (dished dorsal hoof wall, concentric rings).  For 
cost purposes, the feet were not radiographed and, due to the temperament of the horses and level 
of lameness, the exact cause of the lameness was not investigated.  Each was evaluated by an 
equine surgeon and lameness was graded on a 0-5 scale (AAEP).  For the horses graded 2 or less, 
to ensure statistically significant differences in pressure mat data, lameness was further 
exacerbated by injection of 3 µg lipopolysaccharide (LPS) from E. coli O55:B5 (Sigma-Aldrich, 
St Louis MO) into the right metacarpophalangeal joint after aseptic preparation.  The horses 
were then evaluated via pressure mat (MatScan®, TekScan, Inc. Boston, MA).  The horses were 
then randomly assigned to either receive phenylbutazone (4.4 mg/kg orally once daily) or 
meloxicam (0.6 mg/kg orally once daily) for four days.  The investigators were blinded to the 
treatment drug.  Pressure mat data was obtained at baseline and at 12 hour intervals for four 
days.  At the conclusion of the study, the horses were humanely euthanized with sodium 
pentobarbital after sedation with 1 mg/kg xylazine IV.  The horses were sent to a board certified 
pathologist for histopathologic analysis of the kidneys and gastric mucosa and to evaluate for any 
other adverse effects of the drugs.  The pathologists were also blinded to the treatment group. 
 Statistical analysis 
Pressure mat data was evaluated with computer software (MANUFACTURER).  The 
variables calculated included force, contact area, and stride length.   
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 Aim 3 
Equine PBMCs were harvested from 3 normal horses and 3 of the horses used in Aim 2 
of the study.  Sixty mL of blood was collected via jugular venipuncture into a syringe containing 
3000 u sodium heparin (50 u heparin/mL of blood) once on normal horses and at 0 (baseline 
prior to treatment with NSAID) and 24 hours on Horse 4, and at 0, 24, and 96 hours on Horse 1 
and 2.  To each 50 mL conical tube, 15 mL of complete medium (RPMI 1640 with 5% FBS and 
2% Pen/Strep) was added to 15 mL of whole blood.  The media-diluted blood (30 mL) was 
layered over 10 mL of Ficoll 1.083.  The samples were then centrifuged at 1800-2200 rpm for 30 
minutes at room temperature.  The PBMCs were then collected and placed into a 15 mL conical 
tube and washed twice with 10 mL sterile PBS and centrifuged at 2800-3300 rpm for 10 minutes.  
The cells were then resuspended in 5 mL of complete medium.  The PBMCs obtained from the 
normal horses were treated with 100 ng/mL of LPS for 6 hours.  Messenger RNA was isolated 
from these cells using a commercial kit (Qiagen, Valencia, CA) and analyzed for relative 
concentrations of COX-2 mRNA in the presence or absence of LPS using qRT-PCR (18S 
expression was used as the loading control).  The primers used for PCR are listed in Table 3.1. 
Both PBMCs and protein (whole cell lysates using a commercial lysis buffer, Santa Cruz 
Biotechnology, Santa Cruz, CA) were isolated from treated horses.  The RNA was analyzed 
using qRT-PCR for COX-2 expression while the whole cell lysates were assayed for relative 
protein expression of COX-2 using standard protein electrophoresis and western blotting 
procedures.  Actin served as the loading control.  Protein expression was visualized using 
chemiluminescence (Pierce, Rockford, IL).  Densitometry was used to determine relative protein 
expression (Cell Biosciences, Santa Clara, CA). 
 
Table 3.1 Primers used for qRT-PCR for COX-2 and 18S gene expression from peripheral 
blood mononuclear cells in horses. 
COX-2 Forward 5’-TGGCGAGGTGTATCCGCCCA-3’ 
 Reverse 5’-GGTGTCAGGCACAAGGGGATGC-3’ 
18S Forward 5’-TCGCTCCACCAACTAAGAAC-3’ 
 Reverse 5’-GAGGTTCGAAGACGATCAGA-3’ 
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Chapter 4 - Results 
 Aim 1 
Seven of the 16 horses initially evaluated had gastric ulcer scores of Grade 2 or less and 
were entered into the study.  Of the seven horses included in the study, there were 3 mares, 3 
geldings, and 1 stallion.  The mean age was mean 20.3 ± 7.95 y (10 to 31 y, median: 21 y) and 
mean weight was 508.4 ± 62.8 kg (median: 483 kg).  The weights of the horses did not 
significantly change during the study period (p = 0.95).  Breeds represented included Quarter 
Horse (n = 3), Thoroughbred (n = 2), Arabian (n = 1), and Hanoverian (n = 1), and were 
representative of the regional population. 
Initial and final complete blood count, serum chemistry, and urinalysis were within 
normal limits on all horses.  The changes in white blood cell count, total protein, and creatinine 
concentration were not significantly different over the 14 day period (p = 0.70, p = 0.58, p = 
0.56, respectively). 
The results of the gastric ulcer scores are noted below (Table 4.1).  There was no 
significant difference between pre-treatment gastric ulcer scores and post-drug administration 
ulcer scores (p = 0.1465, 95% CI = -2.40 – 0.40), however two horses had an increase from 
Grade 0 to Grade 3 during the experimental period. 
One horse experienced severe insect hypersensitivity beginning on day 8 of meloxicam 
administration.  Urticaria with ulceration and necrosis of the skin was noted.  Meloxicam 
administration was discontinued and punch biopsies were taken of the affected areas.  
Histopathology revealed severe dermatitis with dermoepidermal clefting, early epidermal 
necrosis, and mild lymphocytic, neutrophilic, and eosinophilic dermal inflammation.  
Dexamethasone was administered at 0.05 mg/kg IV once daily for 3 days and then as a tapering 
dose over 2 weeks.  The lesions healed without incident.  The horse was not re-entered into the 
study and pharmacokinetic data for day 14 was not included in the final analysis.  The CBC, 
serum chemistry, urinalysis, and gastroscopy for this horse were performed on day 12. 
A second horse did not experience any adverse events during meloxicam administration 
but the trough concentration on day 15 of the study was double the amount of the previous 
trough concentrations on days 4 and 10 and those of cohort animals on day 15.  The sample was 
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re-evaluated but the same results were obtained.  The data for this horse was removed from the 
final outcome. 
The calculated pharmacokinetic parameters for meloxicam are presented in Table 4.3 and 
the plasma concentrations are presented in Table 4.4.  The model describes a one-compartment 
model.  Dosage for oral administration ranged from 0.60 to 0.61 mg/kg (mean, 0.61 ± 0.008 
mg/kg).  Plasma clearance was 51.2 ± 11.01 mL/kg/h (range: 44.7 to 55.3 mL/kg/h).  Mean 
steady state volume of distribution over 14 days was 0.37 ± 0.11 L/kg (range: 0.32 to 0.41 L/kg) 
and there was no difference from day 0 to day 14 (p = 0.28).  The MRT ranged from 6.66 to 7.51 
h (mean, 7.18 ± 1.41 h) and was not statistically different from day 0 to day 14 (p = 0.57).  
Terminal half-life was 4.99 ± 1.11 h (range: 4.72 to 5.25 h).  The Cmax (range: 0.91 to 2.78 
µg/mL; mean, 1.82 ± 0.80 µg/mL) was detected 3.48 ± 3.3 h, 1.24 ± 1.24 h, and 1.93 ± 1.30 h 
after meloxicam administration on days 0, 7, and 14, respectively.  There was a statistically 
significant difference between the Tmax on the sample days (p = 0.04). 
Trough concentrations on days 0, 4, 7, 10, and 14 were similar (p = 0.45), which indicate 
steady-state conditions.  This was confirmed with the accumulation ratio of meloxicam during 
the 14 days of administration (range, 0.64 to 1.78; mean, 1.17 ± 0.39). 
 Aim 2 
Mean age of the horses included in this portion of the study was 11 ± 3.16 y (9 to 15 y, 
median: 10.5 y).  All four horses were Quarter Horses and their mean weight was 539.4 ± 40.8 
kg (median: 538.3 kg).  The weights did not significantly change over the experimental period (p 
= 0.95).  There were two geldings and two mares. 
Gastric ulcer scores for all of the horses are shown in Table 4.2.  There was no significant 
difference between the gastric ulcer scoring prior to the start of the experiment and the ulcer 
scores at post-mortem (p = 0.17), however the methods used to evaluate gastric ulcer number and 
severity was different. 
Initial CBC for Horse 1 (meloxicam, LPS) revealed a mild stress leukogram.  This was 
confirmed by the presence of mild hyperglycemia (blood glucose: 145 mg/dL; ref. range: 70-116 
mg/dL).  The urinalysis was within normal limits except for a mild increase in protein (3+ on 
strip, approximately 5 mg/dL on sulfasalicylic acid).  The horse was determined to be Grade II 
lame in the right front limb prior to LPS injection.  After LPS injection, Grade IV lameness was 
27 
 
noted.  The horse tolerated the administration of meloxicam with no adverse events noted.  The 
laboratory analysis on day 4 of treatment showed resolution of the stress leukogram and 
hyperglycemia.  The urinalysis revealed a 3+ protein on the strip but negative on the 
sulfasalicylic acid test.  At post-mortem, rotation of the distal phalanx was noted in both front 
feet.  Histopathologic evaluation of the stomach revealed mild degenerative changes in the 
epithelium of the stomach but this was suspected to be due to post-mortem changes as no 
inflammatory cells were noted.  In the right ventral colon, crypt epithelium loss with infiltration 
of Balantidium coli was shown in the lamina propria.  There were no gross or histopathologic 
changes in the right dorsal colon, the most common location for NSAID-induced changes in the 
large intestine.  In the kidneys, mild multifocal tubular mineralization was found.  This appeared 
to be a chronic change and not associated with NSAID administration. 
A stress leukogram was noted in Horse 2 (phenylbutazone, LPS) and this was also 
accompanied by mild hyperglycemia (blood glucose: 159 mg/dL; ref. range: 70-116 mg/dL).  
Increased protein (3+ on strip, negative on SSA) was noted on the urinalysis.  Baseline lameness 
was Grade II in both front limbs.  After LPS was injected into the right carpus, lameness 
increased to Grade IV.  At the conclusion of the study, leukopenia (white blood cell count: 4.8 
K/µL; ref. range: 6-14 K/µL) due to lymphopenia (0.9 K/µL; ref. range: 1.5-7.7 K/µL) was 
found.  Mild anemia (PCV: 30%; decreased from the initial 40%) was also noted.  The increased 
protein in the urine was resolved.  At post-mortem examination, both forefeet had evidence of 
laminitis with rotation of the third phalanx.  In the cecum, there were large numbers of 
lymphocytes, plasma cells, and eosinophils in the lamina propria.  The enterocytes that line the 
crypts stained more basophilic than normal and goblet cells appeared to be decreased.  There 
were no histopathologic changes in the stomach, right dorsal colon, or kidneys. 
Horse 3 (meloxicam, no LPS) had a stress leukogram and significant hyperglycemia 
(blood glucose: 246 mg/dL).  This horse was more feral than the other 3 horses and handling 
likely induced this response.  The behavior of the horse precluded gathering of a urine sample at 
the beginning and end of the study.  Baseline lameness in this horse was Grade IV in both 
forelimbs.  The laboratory values were within normal limits at the conclusion of the study.  At 
post-mortem examination, the only significant lesion was laminitis in both forelimbs with 
rotation of the third phalanx. 
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Horse 4 (phenylbutazone, no LPS) had a mild stress leukogram, moderate anemia 
(packed cell volume: 25%; ref. range:  32-50%), hyperglycemia (178 mg/dL), increased total 
protein (8.2 g/dL; ref. range: 5.8-7.5 g/dL) due to a hyperglobulinemia (5.4 g/dL; 2.5-4.7 g/dL), 
increased γ-glutamyltransferase (GGT) (66 U/L; ref. range: 6-24 U/L), and mild increase in 
alkaline phosphatase (263 U/L; ref. range: 76-249 U/L) at initial examination.  Due to cost 
limitations, further examination of the liver was not performed.  Increased protein was noted on 
urinalysis (3+ on strip, approximately 5 mg/dL on sulfasalicylic acid).  Baseline lameness was 
Grade III in the left front limb.  Lymphopenia was noted on the CBC at the conclusion of the 
study (0.9 K/µL).  The anemia was significantly worse (19%).  On serum chemistry, 
hyperglycemia (198 mg/dL), decreased total protein (5.3 g/dL) due to hypoalbuminemia (2.3 
g/dL; ref. range: 2.7-3.7 g/dL), decreased total calcium (9.6 mg/dL; ref. range: 11.7-14.8 mg/dL), 
and mildly increased GGT (35 U/L) were noted.  The urinalysis revealed a normal protein level.  
At post-mortem examination, hepatic and vascular amyloidosis with hepatic rupture was noted.   
Overall, there was a statistically significant decrease in the total white blood cell count 
between the pre- and post-experimental period (p = 0.01), but stress may have induced an 
increase in the total white blood cell count (as indicated by increased glucose concentrations and 
behavior of the horses) and, once the horses settled into their new environments, the glucose 
concentration and white blood cell count became more normal.  No significant difference was 
found in the pre- and post-administration total protein and creatinine measurements (p = 0.2159 
and 0.5945, respectively).  All horses tolerated the administration of the medications in molasses. 
 When evaluating force and contact area of each limb and comparing the effect of the 
treatments to baseline measurements, there was a statistically significant increase in both force 
and contact area for the right front limb and left hind limb after treatment with phenylbutazone 
when compared to treatment with meloxicam.  Due to the low number of horses in each group, 
mean and standard error could not be calculated.  Additionally, the data was pooled across time 
points and therefore violates the assumption of independence required for statistical tests to be 
robust.  Evaluation of left front and right hind limb force and contact area could not be 
performed because of insufficient data points secondary to malfunction of the pressure mat. 
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 Aim 3 
Cyclooxygenase-2 expression increased four-fold in PBMCs incubated ex vivo with LPS 
(Figure 4.2).  In PBMCs collected from Horse 1 (meloxicam, LPS), there was a decrease in the 
cycle threshold (CT) value from 30.8 at 0 hours to 26.5 at 24 hours (Figure 4.3).  In Horse 2 
(phenylbutazone, LPS) and Horse 4 (phenylbutazone), there was a 200-fold increase in COX-2 
expression at 96 hours compared to baseline (Figure 4.4). 
Western Blot analysis of the PBMCs collected from Horse 1 (meloxicam, LPS) revealed 
a decrease in COX-2 protein expression at 96 hours compared to baseline.  This is in contrast to 
the results from the qRT-PCR analysis in which an increase in COX-2 gene expression was seen 
at 96 hours.  In Horse 2 (phenylbutazone, LPS), there was a 10% decrease in protein expression 
levels by 24 hours, but a 25% increase in protein levels by 96 hours.  In Horse 4 
(phenylbutazone), there was a 50% decrease in COX-2 protein expression at 96 hours compared 
to baseline. 
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Table 4.1 Gastric ulcer score pre- and post-treatment with oral meloxicam tablets, 0.6 
mg/kg, once daily for 14 days. 
 
 
 
 
 
 
 
 
Table 4.2 Gastric ulcer score pre- and post-treatment for horses in Aim 2 of the study. 
Horse Treatment Gastric Ulcer Score Pre Gastric Ulcer Score Post* 
Horse 1 Meloxicam 2 0 
Horse 2 Phenylbutazone 1 0 
Horse 3 Meloxicam 0 0 
Horse 4 Phenylbutazone 0 0 
*Gastric ulceration scores were performed via histopathology at post-mortem examination, rather than gastroscopy 
prior to death. 
 
Table 4.3 Mean ± SD values for phamacokinetic parameters for multiple doses of 
meloxicam (0.6 mg/kg) administered orally once daily to 7* horses for 14 consecutive days. 
 Multiple doses 
Parameter After 1st dose After 7th dose After last dose* 
Plasma t1/2 (h) 5.25 ± 1.40 4.99 ± 0.62 4.73 ± 1.31 
Tmax (h) 3.48 ± 3.30 1.24 ± 1.24 1.93 ± 1.30 
Cmax (µg/mL) 1.58 ± 0.71 2.07 ± 0.94 1.81 ± 0.76 
AUC (h*µg/mL) 11.22 ± 2.00 14.19 ± 2.92 11.73 ± 2.84 
Accumulation ratio NA 1.31 1.14 
Clearance (mL/h/kg) 55.33 ± 9.10 44.27 ± 9.74 54.24 ± 14.18 
Vdss (L/kg) 0.41 ± 0.10 0.32 ± 0.07 0.37 ± 0.16 
*Parameters for the 14th day were calculated for 5 horses. 
Animal Sex Age Breed Ulcer Score Pre-
Treatment 
Ulcer Score 14 
days Post- 
Horse 1 Gelding 10 y QH 0 0 
Horse 2 Stallion 21 y QH 1 0 
Horse 3 Mare 23 y QH 1 2 
Horse 4 Gelding 31 y Arab 0 3 
Horse 5 Mare 27 y TB 0 3 
Horse 6 Mare 20 y Hanoverian 2 3 
Horse 7 Gelding 10 y TB 0 0 
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Figure 4.1Pharmacokinetic profile of oral meloxicam tablets on Day 1, 7, and 14 after 
administration of 0.6 mg/kg PO every 24 hours for 14 days. 
 
 
Figure 4.2 qRT-PCR for COX-2 gene expression in equine PBMCs incubated ex vivo with 
LPS for 6 hours.  There is a 4-fold increase in COX-2 gene expression in LPS treated cells. 
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Figure 4.3 qRT-PCR performed on mRNA isolated from PBMCs from a horse treated with 
meloxicam (0.6 mg/kg PO q 24 h).  Cycle threshold (CT) values decreased from 30.8 to 26.5 
within 24 hours of administration. 
 
Figure 4.4 qRT-PCR performed on mRNA isolated from PBMCs collected from 2 horses 
treated with phenylbutazone (4.4 mg/kg PO q 24 h).  Cycle threshold values decreased in 
both horses at 96 hours.  
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Chapter 5 - Discussion 
Oral meloxicam tablets were well tolerated in all horses.  A limitation of this study 
included small sample size and this was a result of the inability to find a suitable horse without 
gastric ulceration.  As gastric ulceration is prevalent in horses of all disciplines, this was not 
unexpected.  Although there was not a statistically significant increase in gastric ulcer scoring 
over the 14 day period, three horses did experience an increase in gastric ulcer grade and two of 
these horses had clinical signs associated with the ulceration (inappetance).  These two horses 
were not part of the teaching herd and were transported to the testing site the morning of 
sampling and returned home the following day on three occasions.  Transport stress, a new and 
changing environment, and handling of these horses may have contributed to the increase in 
gastric ulcer score.  Ideally, two control horses that were transported in the same manner but not 
administered medications would be required to determine whether the medications or the 
changing environments resulted in the worsening of gastric ulceration.  Previous studies using 
label doses of phenylbutazone (2.2 mg/kg) given orally twice daily for 14 days indicate that the 
drug is safe over this period of time (Andrews 2009).  As there were no changes in total protein, 
urinalysis, or creatinine measurements over the 14 day period, it does not appear that meloxicam 
affects the kidneys or results in right dorsal colon ulceration when given in this manner. 
Plasma clearance obtained in this study was slightly higher (mean, 51.2 ± 11.01 mL/kg/h) 
than that obtained in previous studies using intravenous and oral suspension formulations (Lees 
1991, Toutain 2004a, Sinclair 2006) but lower than that obtained in one study using the 
intravenous form (mean, 81 mL/kg/h; Toutain 2004b).  The origin of these differences is unclear; 
however, differences in analysis and population may affect results. 
The terminal half-lives in the previous studies reported are highly variable.  This is likely 
due to the methods of analysis, where the limit of quantification may have not been sufficiently 
low enough to monitor the decrease of plasma concentrations for a long enough period of time to 
determine the true terminal portion of the curve.  A terminal half-life of approximately 5 hours is 
sufficient to justify a once-daily dosing regimen for an NSAID and yet avoid any accumulation 
as indicated by the accumulation ratio which was close to 1 (1.17 ± 0.39).  The plasma patterns 
of meloxicam should be nearly identical after each administration and should preclude the use of 
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a loading dose.  The steady state volume of distribution was limited (0.37 ± 0.11 L/kg), likely a 
result of extensive protein binding. 
The decision to allow the horses to be fed during our study allowed this to be a more 
practical and clinically applicable study.  The bioavailability of the drug is not changed with 
feeding (Toutain 2004b); however, MRT, MAT, and Tmax are significantly greater and Cmax 
significantly lower in fed than in nonfed horses.  Feeding substantially lowers the rate of drug 
absorption but does not appear to affect bioavailability.  The bioavailability could not be 
evaluated in this study because intravenous data was not obtained.  The Cmax obtained in our 
study (1.82 ± 0.8 µg/mL) was very similar to that found in fed horses in another study (1.73 ± 
0.61 µg/mL; Toutain 2004a); however, the Tmax was slightly shorter (mean: 2.22 ± 1.95 µg/mL) 
than in the fed horses of the Toutain study (3.4 ± 1.19 h (fed), 1.5 ± 1.07 h (non-fed)). 
Four horses were used in the second aim of the study.  This was due to limits in budget 
and availability of horses that had not been administered NSAIDs in the last 6 months.  The 
horses that were obtained had been previously used as serum producing horses.  The behavior of 
the horses (semi-feral) and budget limitations restricted our evaluation of lameness to pressure 
mat analysis only.  The behavior of the horses also affected the evaluation of the pressure mat 
data as one of the horses damaged the pressure mat during the evaluation.  Budget limitations 
also affected the ability to evaluate gastric ulcer scoring via gastroscopy at the end of the study.  
However, endoscopic scoring of gastric ulceration tends to underestimate the number, severity, 
and depth of gastric ulcers compared to histopathology (Andrews 2002) and therefore, scoring at 
post-mortem was the more sensitive test. 
One horse experienced leukopenia and evidence of typhlocolitis on histology at post-
mortem, although no clinical evidence was noted.  It is likely that this was a result of systemic 
absorption of LPS from the carpus joint.  Another horse had acute hepatic rupture noted at post-
mortem, secondary to hepatic amyloidosis.  A large amount of blood filled the abdomen and this 
explained the significant anemia and hypoproteinemia.  All of the horses had been used as 
hyperimmunized serum donors and amyloidosis has been associated with the repeated injections 
of the endotoxin-releasing bacteria Escherichia coli and Pasteurella multocida (Abdelkader 
1991).  Occasionally, horses will die with no clinical signs; the only clinical sign this horse 
showed was a decreased appetite the morning of the day of euthanasia.  In addition to the hepatic 
findings, there was chronic rotation of the third phalanx of both front feet and chronic 
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tubulointerstitial nephritis.  There were no histopathologic changes in the right dorsal colon 
except for vascular amyloidosis. 
Due to pressure mat malfunction, a full analysis of the data obtained could not be 
performed.  However, the data suggests that meloxicam is not as potent as phenylbutazone for 
lameness pain.  Induction of lameness with LPS presents a challenge in evaluating daily 
lameness changes due to the steady improvement in lameness over time.  A more consistent 
method of lameness induction may have included a shoe that allows for a reversible model of 
lameness (Foreman 2010).  This was a pilot study and the aim was to determine if there were any 
improvements noted with meloxicam administration.  Although the horses were not critically 
evaluated for lameness grade, each horse appeared clinically more comfortable and able to 
mobilize around the stall easier after administration of both medications. 
Other parameters that could have been measured during the second aim of the study 
included serum concentrations of meloxicam during the administration period and comparing the 
concentration at which 50% of the lameness was reduced (EC50 and ED50).  Additionally, the 
circumference of the carpal joint, the angle of the carpus at rest, maximal forced flexion angle of 
the carpus, and pedometry may have been used to evaluate additional parameters of lameness 
pain. 
Incubation of PBMCs with LPS resulted in an increase in gene expression of COX-2 in 
normal horses.  Systemically, injection of LPS into the metacarpophalangeal joint resulted in an 
increase in both gene and protein expression of COX-2 and this increase was variably attenuated 
by meloxicam and phenylbutazone.  With the very small sample size used in this study, it is 
impossible to interpret the clinical usefulness of these results, but rather indicates the need for 
further research to explain the variability found in the results. 
In conclusion, oral meloxicam tablets administered at 0.6 mg/kg orally once daily to 
horses are well-tolerated and we found similar pharmacokinetics to the oral suspension 
formulation.  Additionally, administration of this medication over 14 days did not result in 
evidence of renal or gastrointestinal changes.  Although inferior to phenylbutazone for induced 
and naturally occurring lameness, it may be considered an alternative due to its selective or 
preferential COX-2 inhibition. 
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